Free Trial
OTCMKTS:BETRF

BetterLife Pharma (BETRF) Stock Price, News & Analysis

BetterLife Pharma logo
$0.07 0.00 (-4.35%)
As of 06/12/2025 12:54 PM Eastern

About BetterLife Pharma Stock (OTCMKTS:BETRF)

Key Stats

Today's Range
$0.07
$0.07
50-Day Range
$0.05
$0.09
52-Week Range
$0.05
$0.15
Volume
1,555 shs
Average Volume
21,628 shs
Market Capitalization
$8.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Receive BETRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BetterLife Pharma and its competitors with MarketBeat's FREE daily newsletter.

BETRF Stock News Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
BetterLife Announces Debt Settlements
BetterLife appoints Andre Beaudry as corporate advisor
See More Headlines

BETRF Stock Analysis - Frequently Asked Questions

BetterLife Pharma's stock was trading at $0.0720 at the beginning of the year. Since then, BETRF shares have decreased by 8.3% and is now trading at $0.0660.
View the best growth stocks for 2025 here
.

Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
6/14/2025
Next Earnings (Estimated)
6/25/2025
Fiscal Year End
1/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BETRF
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-1.32

Miscellaneous

Free Float
84,449,000
Market Cap
$8.54 million
Optionable
Not Optionable
Beta
1.52
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:BETRF) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners